Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) trades at $356.83, while the average Wall Street price target sits at $484.40. That leaves roughly a 36% gap between current price and Street consensus.
Intuitive builds the da Vinci robotic surgery platform and the Ion lung biopsy system, dominating soft tissue surgical robotics. Wall Street has debated whether that moat holds amid tariffs, softer U.S. procedure growth, and da Vinci 5 margin questions.
Bernstein, the most bullish analyst on the name, targets $685, implying almost 92% upside from here.
The Selloff That Broke a Compounder
ISRG has fallen 37% year to date, from $566.36 at the end of 2025 to today’s level. That drawdown well exceeds 30% while the underlying business kept growing.
Q2 2026 was a clean beat. Revenue came in at $2.89 billion, up 18.54% year over year, and non-GAAP EPS of $2.80 topped the $2.5037 consensus. It was the fifth consecutive quarter of beating estimates. Shares still dropped 11.25% the day after earnings.
The guide spooked investors. Management guided full-year da Vinci procedure growth to 13.5% to 15.5%, down from 18% in 2025. U.S. da Vinci growth decelerated from 14% in Q1 to 12% in Q2, with CEO Dave Rosa citing ACA premium dynamics, high-single-digit declines in bariatric cases from GLP-1 usage, and China tender softness. Tariff exposure across Mexico, Germany, and China manufacturing compressed the multiple hard.
Why Bernstein Still Sees a Double
Bernstein maintains an Outperform rating and cut its target from $750 to $685 to account for near-term procedure volatility and multiple compression. Even after the trim, it remains the most optimistic shop on the Street. The thesis rests on three pillars: a da Vinci 5 upgrade cycle multiplier, recurring revenue durability, and an international monopolistic moat.
Q2 data supports each leg. Da Vinci 5 placements hit 246 of 468 total placements, with U.S. placements up 24% as customers upgrade from Xi. Recurring revenue was $2.47 billion, roughly 85% of the total. International procedures grew 21%, with Europe and Asia both at 20%. Non-GAAP gross margin expanded to 70.0%, aided by a $36 million tariff refund but still up meaningfully year over year.
Consensus remains constructive. Ratings break out to 22 Buy, 9 Hold, and 2 Sell, and CEO commentary has been consistently positive through recent quarters. The bull case ties recovery to procedure growth reacceleration in 2027 as deferred cases return, ongoing da Vinci 5 mix shift lifting system ASPs (already $1.6 million versus $1.5 million prior year), and the Extended Use Program on ENDORIST instruments broadening adoption in cost-constrained markets.
Peers Held Up While ISRG Slid
This selloff is largely idiosyncratic. Nearest large-cap med device peers have declined far less.
Medtronic (NYSE:MDT) is down 10.83% year to date at $84.22, with its Hugo robotic surgery platform now FDA cleared and Cardiac Ablation growing 78%. Analyst posture skews Buy with modest single-digit implied upside to consensus.
Stryker (NYSE:SYK) sits at $336.74, off just 3.67% year to date after a Q1 cyber incident. The Mako orthopedic robotics platform and Inari vascular deal have kept analysts constructive, with Buy ratings dominant and mid-teens implied upside.
The largest analyst-implied upside in this peer group sits with ISRG by a wide margin. This is a single-name reset.
What the Numbers Actually Say
At $356.83 against a consensus target of $484.40, implied upside runs roughly 36%. Bernstein’s $685 stretches that to nearly 92%.
ISRG is down 37% year to date and 28.04% over the past year, while the S&P 500 is up 8.38% year to date and 16.01% over 12 months. Shares trade at a P/E of roughly 39, compressed from 2025 premium multiples.
Cash on the balance sheet is $8.6 billion, and the company repurchased $379 million of stock in Q2 at an average price of $439. Management is buying above current levels.
The Verdict on a $130 Billion Reset
The bull case for Intuitive Surgical holds if the procedure growth deceleration is a 2026 pothole rather than a new normal. Recovery runs through da Vinci 5 mix continuing to lift ASPs and service revenue, ACA-related patient deferrals unwinding as coverage stabilizes, and tariff impacts staying within the 100 basis points already baked into guidance. Recurring revenue at 85% of the total is a hard base to break.
The bear case takes over if U.S. procedure growth stalls in the low double digits, if China competition and pricing pressure escalate beyond current tender softness, or if further tariffs blow through management’s guardrails. A 39x P/E on a business growing procedures 13% to 15% leaves little room for another guide down.
On balance, lean constructive. The peer set remains committed to surgical robotics, the balance sheet is fortress, and management is repurchasing above current price. Bernstein’s $685 is aspirational, but consensus at $484 looks achievable if the 2027 comp resets even modestly favorably.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks